A detailed history of Metis Global Partners, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Metis Global Partners, LLC holds 100,644 shares of BMY stock, worth $5.84 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
100,644
Previous 95,957 4.88%
Holding current value
$5.84 Million
Previous $3.99 Million 30.69%
% of portfolio
0.17%
Previous 0.14%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$39.66 - $51.75 $185,886 - $242,552
4,687 Added 4.88%
100,644 $5.21 Million
Q2 2024

Aug 06, 2024

SELL
$40.25 - $52.99 $846,980 - $1.12 Million
-21,043 Reduced 17.99%
95,957 $3.99 Million
Q1 2024

May 06, 2024

SELL
$47.98 - $54.4 $108,002 - $122,454
-2,251 Reduced 1.89%
117,000 $6.34 Million
Q4 2023

Feb 06, 2024

BUY
$48.48 - $57.85 $847,381 - $1.01 Million
17,479 Added 17.17%
119,251 $6.12 Million
Q3 2023

Nov 07, 2023

BUY
$57.89 - $64.73 $759,632 - $849,387
13,122 Added 14.8%
101,772 $5.91 Million
Q2 2023

Aug 07, 2023

SELL
$63.71 - $70.74 $31,600 - $35,087
-496 Reduced 0.56%
88,650 $5.67 Million
Q1 2023

May 08, 2023

BUY
$65.71 - $74.53 $1.45 Million - $1.65 Million
22,128 Added 33.02%
89,146 $6.18 Million
Q4 2022

Feb 07, 2023

BUY
$68.48 - $81.09 $1.94 Million - $2.3 Million
28,364 Added 73.38%
67,018 $4.82 Million
Q3 2022

Nov 08, 2022

BUY
$0.13 - $76.84 $239 - $141,846
1,846 Added 5.02%
38,654 $2.75 Million
Q2 2022

Aug 08, 2022

BUY
$72.62 - $79.98 $133,548 - $147,083
1,839 Added 5.26%
36,808 $2.83 Million
Q1 2022

May 03, 2022

BUY
$61.48 - $73.72 $959,518 - $1.15 Million
15,607 Added 80.61%
34,969 $2.55 Million
Q4 2021

Feb 11, 2022

BUY
$53.63 - $62.52 $1.04 Million - $1.21 Million
19,362 New
19,362 $1.21 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Metis Global Partners, LLC Portfolio

Follow Metis Global Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metis Global Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Metis Global Partners, LLC with notifications on news.